glp-1 dementia study Studies comparing effects of GLP1-receptor agonist on risk of How GLP-1s Could Transform Alzheimer's

CD36-Mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-Targeted therapies

Bottom Line GLP-1 drugs are not currently FDA-approved for people who dont have obesity or diabetes, but clinicians increasingly recognize the benefits of losing 10 to 30 pounds with GLP-1 therapy

Many insurance companies are dropping non-Medicare coverage for the drugs

For most compounded semaglutide protocols, a 0.5 ml (50 unit) insulin syringe is the best starting point

doi:10.1249/JSR.0b013e318180735c (4) Fielding R, Riede L, Lugo JP, Bellamine A

A 5 mg BPC-157 vial ($30-50) lasts 10-20 days at 250-500 mcg daily